Drug Metabolism: Evolution

Abstract

Advances in molecular biology and genetics have given us a much better understanding of the evolution of drug metabolism. Genes encoding drug‐metabolizing enzymes, as well as some drug receptors and transporters, have functioned in many signal transduction pathways in bacteria and yeast and, more recently, in countless critical life processes in plants and animals – events that emerged millions of years before the establishment of pharmaceutical companies and drug stores.

Keywords: drug metabolism; evolution; receptors; transporters; polymorphisms; human populations

Figure 1.

Diagram of the fate of drugs (R) entering the cell. Drugs might enter the cell by either passive diffusion or active transporters. Either the parent nonmetabolized drug or metabolite reaches its clinical target (efficacy), or the drug or metabolite causes toxicity via perturbation of the cell cycle or covalent binding. Reception mechanisms are able to detect the drug as a ‘signal’, and sometimes can up‐ or downregulate Phase I and Phase II drug‐metabolizing enzymes (Nebert, ). The encircled plus and minus signs denote positive and negative regulation respectively. Transporter proteins can also assist in moving the parent drug and metabolites out of the cell. O=Oxygen atom; conjugate=any polar moiety that is transferred to Phase I products by Phase II DMEs. (Reproduced with permission from publisher, Nebert .)

Figure 2.

Summary of the probable relationship between drug‐metabolizing enzymes (DMEs) and all nonpeptide endogenous ligands that stimulate signal transduction pathways, affecting innumerable critical cellular functions. (Reproduced with permission from publisher; modified from Nebert .)

close

References

Blumberg B, Kang H, Bolado J Jr, et al. (1998) BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites. Genes and Development 12: 1269–1277.

Dalton TP, Shertzer HG and Puga A (1999) Regulation of gene expression by reactive oxygen. Annual Review of Pharmacology and Toxicology 39: 67–101.

Erlanson DA, Braisted AC, Raphael DR, et al. (2000) Site‐directed ligand discovery. Proceedings of the National Academy of Sciences of the United States of America 97: 9367–9372.

Fitzgerald ML, Moore KJ and Freeman MW (2002) Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. Journal of Molecular Medicine 80: 271–281.

Gonzalez FJ and Nebert DW (1990) Evolution of the P450 gene superfamily: animal–plant ‘warfare,’ molecular drive, and human genetic differences in drug oxidation. Trends in Genetics 6: 182–186.

Kvackajova‐Kisucka J, Barancik M and Breier A (2001) Drug transporters and their role in multidrug resistance of neoplastic cells. General Physiology and Biophysics 20: 215–237.

Levitzki A and Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782–1788.

Nebert DW (1990) Growth signal pathways. Nature 347: 709–710.

Nebert DW (1991) Proposed role of drug‐metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. Molecular Endocrinology 5: 1203–1214.

Nebert DW (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clinical Genetics 56: 247–258.

Nebert DW, Adesnik M, Coon MJ, et al. (1987) The P450 gene superfamily. Recommended nomenclature. DNA 6: 1–11.

Nebert DW and Dieter MZ (2000) The evolution of drug metabolism. Pharmacology 61: 124–135.

Nebert DW and Gonzalez FJ (1987) P450 genes: structure, evolution and regulation. Annual Review of Biochemistry 56: 945–993.

Nebert DW, Nelson DR, Coon MJ, et al. (1991) The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA and Cell Biology 10: 1–14.

Nebert DW, Roe AL, Dieter MZ, et al. (2000) Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochemical Pharmacology 59: 65–85.

Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. The Lancet 360: 1155–1162.

Peel SA (2001) The ABC transporter genes of Plasmodium falciparum and drug resistance. Drug Resistance Update 4: 66–74.

Further Reading

Courvalin P and Trieu‐Cuot P (2001) Minimizing potential resistance: the molecular view. Clinical Infectious Diseases 33(supplement 3): S157–S160.

Jack DL, Yang NM and Saier MH Jr (2001) The drug/metabolite transporter superfamily. European Journal of Biochemistry 268: 3620–3639.

Saier MH Jr and Paulsen IT (2001) Phylogeny of multidrug transporters. Seminars in Cell and Developmental Biology 12: 205–213.

Tudzynski P, Correia T and Keller U (2001) Biotechnology and genetics of ergot alkaloids. Applied Microbiology and Biotechnology 57: 593–605.

Web Links

Cytochrome P450 Homepage http://drnelson.utmem.edu/cytochromeP450.html

OMIM Online Mendelian Inheritance in Man. This database is a catalog of human genes and genetic disorders authored and edited by Dr. Victor A. McKusick and colleagues at Johns Hopkins and elsewhere, and developed for the World Wide Web by the National Center for Biotechnology Information. The database contains textual information, pictures and reference information. It also contains copious links to NCBI's Entrez database of MEDLINE articles and sequence information. The OMIM Morbid Map, a catalog of genetic disease and their cytogenetic map locations arranged alphabetically by disease, is now also available. http://www.ncbi.nlm.nih.gov/omim/

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Nebert, Daniel W(Sep 2006) Drug Metabolism: Evolution. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0006143]